Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.83 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16164223 | 0.92 | SCN9A (0.98) | SCN9ACD274TSHRPOLBKCNH2 | |
| SCHEMBL787296 | 0.91 | SCN9A (1.00) | SCN9ATSHRMAPTPOLBKCNH2 | |
| SCHEMBL14919950 | 0.83 | SCN9A (1.00) | SCN9ATSHR | |
| SCHEMBL16174381 | 0.80 | SCN9A (0.66) | SCN9ACD274TSHRHPGDS | |
| SCHEMBL14920244 | 0.80 | SCN9A (1.00) | SCN9A | |
| SCHEMBL14919913 | 0.80 | SCN9A (0.74) | SCN9AALDH1A1 | |
| SCHEMBL14921893 | 0.79 | SCN9A (0.74) | SCN9AHSD17B10CYP3A4HPGD | |
| SCHEMBL14919992 | 0.78 | SCN9A (1.00) | SCN9A | |
| Ammonia Solution, Strong SCHEMBL16164296 | 0.77 | SCN9A (0.98) | SCN9A | |
| SCHEMBL14919879 | 0.77 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, SCN1A | SCN9A 23/4885CD274 4784/4885TSHR 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.